Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 6INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Classical hematology 1

Conditions

Thrombocytopenia 5Leukemia, Myeloid, Acute 3Myelodysplastic Syndromes 2Sarcoma 1Purpura, Thrombocytopenic, Idiopathic 1Myeloproliferative Disorders 1Leukemia 1Jacobs syndrome 1Healthy Adults 1

Interventions

Cytarabine 21Imatinib Mesylate 20venetoclax 16Azacitidine 16nilotinib 15Cyclophosphamide 15fludarabine 13Dasatinib 12blinatumomab 10Rituximab 10quizartinib 7Gemtuzumab 7Daunorubicin 7ruxolitinib 6Drug Therapy 6Clofarabine 6Bendamustine Hydrochloride 6AP 1903 reagent 6ponatinib 5fludarabine phosphate 5Whole-Body Irradiation 5Vincristine 5Mycophenolic Acid 5Methotrexate 5Granulocyte Colony-Stimulating Factor 5Dexamethasone 5vosaroxin 4revumenib 4rasburicase 4forodesine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Leukemia × eltrombopag × Clear all
NCT01890746 2019-09-11

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

Novartis

Phase 2 Completed
148 enrolled 42 charts
Classical hematologyOther hematologic neoplasm

Leukemia, Thrombocytopenia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡